Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLN 978

Next Previous
Drug Profile

CLN 978

Alternative Names: CD19xCD3; CLN-978; NexGem

Latest Information Update: 04 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cullinan Therapeutics
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Discontinued Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 25 Oct 2025 Pharmacodynamics data from a preclinical trial in rheumatoid arthritis, Sjögren's disease and systemic lupus erythematosus released by Cullinan Therapeutics
  • 07 Aug 2025 Phase-I clinical trials in Sjogren's syndrome in Europe (SC) before August 2025
  • 07 Aug 2025 Cullinan Therapeutics receives regulatory approval for Phase-I clinical trials in Sjogren's syndrome in Europe before August 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top